Page 116 - Bio Engineering Approaches to Cancer Diagnosis and Treatment
P. 116
114 CHAPTER 4 Immunotherapy
[110] B.L. Stein, R.V. Tiu, Biological rationale and clinical use of interferon in the classical
BCR-ABL-negative myeloproliferative neoplasms, J. Interferon Cytokine Res. 33 (4)
(2013) 145–153.
[111] A. Ribas, J.D. Wolchok, Cancer immunotherapy using checkpoint blockade, Science
359 (6382) (2018) 1350–1355.
[112] S.C. Wei, C.R. Duffy, J.P. Allison, Fundamental mechanisms of immune checkpoint
blockade therapy, Can. Dis. 8 (9) (2018) 1069–1086.
[113] J.M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel, S. Postel-Vinay, C.
Massard, Immune-related adverse events with immune checkpoint blockade: a compre-
hensive review, Eur. J. Can. 54 (2016) 139–148.
[114] R. Ravi, K.A. Noonan, V. Pham, R. Bedi, A. Zhavoronkov, I.V. Ozerov, S. Nimmagadda,
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously dis-
able TGFβ enhance the efficacy of cancer immunotherapy, Nature Comm. 9 (1) (2018)
741.
